Prof HUNG Fan Ngai, Ivan

Prof Hung

Ru Chien and Helen Lieh Professor in Health Sciences Pedagogy
Assistant Dean (Admissions), Li Ka Shing Faculty of Medicine, The University of Hong Kong
Chief of Infectious Diseases Division

  • MBChB (Bristol), MD (HK), MRCP (UK), FRCP (Lon, Edin), FHKCP, FHKAM (Medicine), PDipID (HK)
Professor Ivan Fan Ngai HUNG is currently Clinical Professor and Assistant Dean (Admissions), Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong and Honorary Consultant in Queen Mary Hospital, Hong Kong SAR. He is a dual specialist in Infectious Disease and Gastroenterology & Hepatology. He obtained his medical degree from the University of Bristol Medical School, England in 1996. After working in the University of Cambridge Medical School and Charing Cross Hospital, the Imperial College Medical School, London, he returned to Hong Kong in 1999 and joined the Department of Medicine, Queen Mary Hospital. After obtaining his MRCP, he underwent subspecialty training in Infectious Diseases, followed by Gastroenterology and Hepatology. He was a Visiting Fellow at the Division of Geographical Medicine and Infectious Diseases, Tufts-New England Medical Center, Boston, USA. He obtained his M.D. degree from the University of Hong Kong in 2011 and was awarded the Sir Patrick Manson Gold Medal award for best M.D. thesis. He is currently the Fellow of Royal Colleges of Physicians of London and Edinburgh.

He has published more than 150 international peer reviewed original articles, including research articles in the Lancet, the Lancet Infectious Diseases and the Clinical Infectious Diseases. He and his team have pioneered the use of topical imiquimod before intradermal influenza vaccination, which results in protection against heterologous non-vaccine and antigenically drifted viruses (Lancet Infectious Diseases). His team was also the first to prove convalescent plasma and H-IVIG reduced mortality in patients with severe influenza infection in prospective clinical trials (Clinical Infectious Diseases and Chest).

His research interest includes vaccine, innovative treatment of severe influenza and prevention of pneumococcal infection, treatment of resistant Helicobacter pylori infection, novel endoscopy techniques, and hepatitis B related hepatocellular carcinoma. He is ranked as University of Hong Kong top 1% scientists in 2013, with an H-index of 32. He is the Board & Founding Member of the World Association for Infectious Diseases and Immunological Disorders (WAidid), member of 8 international advisory boards for vaccine and infectious diseases. He is Section Editor for the BMC Infectious Diseases and editorial board member of the Journal of Gastroenterology and Hepatology, Journal of Interventional Gastroenterology and the Scientific World Journal. He is a regular reviewer for journals including the Lancet, Annals of Internal Medicine, Vaccine, Clinical Vaccine and Immunology, Endocrine, Clinical Obesity, Gastrointestinal Endoscopy, Helicobacter, Journal of Gastroenterology and Hepatology, Digestion and the Hong Kong Journal of Medicine.


Research Profile
  1. Treatment of influenza infection
  2. Vaccine
  3. Emerging infectious diseases
  4. Treatment of Helicobacter pylori infection
  5. Endoscopy techniques

Selected Publications
  1. Hung IF, Zhang AJ, To KK, Chan JF, Li P, Wong TL, Zhang R, Chan TC, Chan BC, Wai HH, Chan LW, Fong HP, Hui RK, Kong KL, Leung AC, Ngan AH, Tsang LW, Yeung AP, Yiu GC, Yung W, Lau JY, Chen H, Chan KH, Yuen KY.  Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.  Lancet Infectious Diseases 2016 Feb; 16(2):209-18.
  2. Hung IF, To KK, Lee CK, Lee KL, Yan WW, Chan K, Chan WM, Ngai CW, Law KI, Chow FL, Liu R, Lai KY, Lau CC, Liu SH, Chan KH, Lin CK, Yuen KY. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection. Chest 2013;144:464-73
  3. Hung IF, Tantawichien T, Tsai YH, Patil S, Zotomayor R. Regional epidemiology of invasive pneumococcal disease in Asian adults: epidemiology, disease burden, serotype distribution, and antimicrobial resistance patterns and prevention. Int J Infect Dis. 2013 Jun;17(6):e364-73.
  4. Liu KS, Hung IF, Seto WK, Tong T, Hsu AS, Lam FY, But DY, Wong SY, Leung WK. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical first line and second line treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Gut 2013 Dec 2 doi:10.1136/gutjnl-2013-306120. [Epub ahead of print]
  5. Chan TC, Luk JK, Chan FH, Chan TC, Chu LW, Hung IF. Factors associated with seasonal influenza vaccination in Chinese nursing home older adults. J Am Med Dir Assoc. 2013 Oct;14(10):772-4.
  6. Hung IF, Levin Y, To KK, Chan KH, Zhang AJ, Li P, Li C, Xu T, Wong TY, Yuen KY. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine. 2012 Oct 5;30(45):6427-35.
  7. Cheng VC, To KK, Tse H, Hung IF, Yuen KY. Two years after pandemic influenza A/2009/H1N1: what have we learned? Clin Microbiol Rev. 2012 Apr;25(2):223-63.
  8. Hung IF, Levin Y, To KK. Quantitative and qualitative analysis of antibody response after dose sparing intradermal 2009 H1N1 vaccination. Vaccine. 2012 Apr 5;30(17):2707-8.
  9. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, Liu R, Watt CL, Chan WM, Lai KY, Koo CK, Buckley T, Chow FL, Wong KK, Chan HS, Ching CK, Tang BS, Lau CC, Li IW, Liu SH, Chan KH, Lin CK, Yuen KY. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011 Feb 15;52(4):447-56.
  10. Hung IF, Leung AY, Chu DW, Leung D, Cheung T, Chan CK, Lam CL, Liu SH, Chu CM, Ho PL, Chan S, Lam TH, Liang R, Yuen KY. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcal and influenza vaccination: a prospective cohort study. Clin Infect Dis. 2010 Nov 1;51(9):1007-16.
  11. Hung IF, To KK, Lee CK, Lin CK, Chan JF, Tse H, Cheng VC, Chen H, Ho PL, Tse CW, Ng TK, Que TL, Chan KH, Yuen KY. Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009.Clin Infect Dis. 2010 Aug 1;51(3):274-9.
  12. Wong HK, Lee CK, Hung IF, Leung JN, Hong J, Yuen KY, Lin CK. Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection. Transfusion. 2010 Sep;50(9):1967-71.
  13. To KK, Hung IF, Li IW, Lee KL, Koo CK, Yan WW, Liu R, Ho KY, Chu KH, Watt CL, Luk WK, Lai KY, Chow FL, Mok T, Buckley T, Chan JF, Wong SS, Zheng B, Chen H, Lau CC, Tse H, Cheng VC, Chan KH, Yuen KY. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection.Clin Infect Dis. 2010 Mar 15;50(6):850-9.
  14. Li IW, Hung IF, To KK, Chan KH, Wong SS, Chan JF, Cheng VC, Tsang OT, Lai ST, Lau YL, Yuen KY. The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment. Chest. 2010 Apr;137(4):759-68.
  15. Hung IF, Chan P, Leung S, Chan FS, Hsu A, But D, Seto WK, Wong SY, Chan CK, Gu Q, Tong TS, Cheung TK, Chu KM, Wong BC. Clarithromycin-amoxycillin-containing triple therapy: a valid empirical first-line treatment for Helicobacter pylori eradication in Hong Kong? Helicobacter 2009 Dec;14(6):505-11.
  16. Hung IF, Poon RT, Lai CL, Fung J, Fan ST, Yuen MF. Recurrence of hepatitis B-related hepatocellular carcinoma is associated with high viral load at the time of resection. Am J Gastroenterol. 2008 Jul;103(7):1663-73.
  17. Hung IF, Wu AK, Cheng VC, Tang BS, To KW, Yeung CK, Woo PC, Lau SK, Cheung BM, Yuen KY. Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study. Clin Infect Dis. 2005 Aug 1;41(3):291-300
  18. Hung IF, Cheng VC, Wu AK, Tang BS, Chan KH, Chu CM, Wong MM, Hui WT, Poon LL, Tse DM, Chan KS, Woo PC, Lau SK, Peiris JS, Yuen KY. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis. 2004 Sep;10(9):1550-7.
  19. Woo PC, Lau SK, Tsoi HW, Chan KH, Wong BH, Che XY, Tam VK, Tam SC, Cheng VC, Hung IF, Wong SS, Zheng BJ, Guan Y, Yuen KY. Relative rates of non-pneumonic SARS coronavirus infection and SARS coronavirus pneumonia. Lancet. 2004 Mar 13;363(9412):841-5.
  20. Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, Law KI, Tang BS, Hon TY, Chan CS, Chan KH, Ng JS, Zheng BJ, Ng WL, Lai RW, Guan Y, Yuen KY; HKU/UCH SARS Study Group. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003 May 24;361(9371):1767-72.

Research Funding
  1. RGC-General Research Fund 2014-15: A double blind randomized controlled trial of intradermal hepatitis B vaccination with topical imiquimod in dialyzed patients with chronic renal failure (Project ref: 17108614) (HK$551,319)
  2. RGC- General Research Fund 2013-14: Efficacy and safety of a novel intradermal live-attenuated varicella zoster vaccine in hematopoietic-cell transplantation donors: a randomized double-blind placebo-controlled trial (Project ref: HKU 768313M) (HK$691,267)
  3. HMRF 2019-2022: Commissioned Study on Influenza Vaccine with Imiquimod in Elderly and Chronic Illness Subjects (HK$ 10,494,340)
  4. HMRF 2019-2022: Commissioned Programmes for Influenza Research: A double-blind, randomised, controlled trial on flufenamic acid, clarithromycin and oseltamivir combination for hospitalised influenza infection  (HK$ 4,770,144)
  5. HMRF 2015-20: Commissioned Research on CID Phase III – HKU: Immunogenicity of intradermal quadrivalent influenza and 13-valent pneumococcal conjugated vaccination with topical imiquimod in at risk individuals (Project ref: HKM-15-M08) (HK$2,400,000)
  6. HMRF 2014-15: A double-blind randomized controlled trial of 13-valent pneumococcal conjugated vaccine in patients with chronic illness (Project ref: 14130782) (HK826,320)
  7. HMRF 2014-15: Commissioned Studies – Treatment of severe influenza A infection with celecoxib: a double blind randomized controlled trial (Project ref: RRG-18) (HK$786,352)
  8. Research Fund for the Control of Infectious Disease (RFCID): Efficacy Combined Influenza and 23-Valent Polysaccharide Pneumococcal Vaccines in Patients with Chronic Illness 2009-2014 (HK$1,000,000)
  9. Research Fund for the Control of Infectious Disease (RFCID): Commissioned Study on Human Swine Influenza Research 2009-2012 (Project ref: CS-07) (HK$2,825,754)

International top 1% scholars in 2018 and 2013 according to the Thomson Reuter ISI’s Essential Science Indicators
2019 Outstanding Researcher Award (ORA) (The University of Hong Kong)
2018 Ru Chien & Helen Lieh Endowed Professorship in Health Sciences Pedagogy
2017 Distinguished Young Fellow  (Hong Kong Academy of Medicine)
2017 Research Output Prize (PI) (LKS Faculty of Medicine, The University of Hong Kong)
2016 Richard Yu Lectureship and Medal  (Hong Kong College of Physicians)
2011 Best Oral Presentation Award – 19th European Gastroenterology Week (UEGW)
2011 Sir Patrick Manson Gold Medal – Best M.D.Thesis (The University of Hong Kong)
2011 Distinguished Research Paper Award for Young Investigators (Hong Kong College of Physicians)
2003 Anti-SARS Gold Badge Award (Hospital Authority)

Key Offices
  1. Assistant Dean (Admissions), Teaching and Learning, LKS Faculty of Medicine, The University of Hong Kong (Since 2018)
  2. Board & Founding Member, World Association for Infectious Diseases and Immunological Disorders (WAidid) (Since 2014)
  3. Member, GeoSentinel – International Society of Travel Medicine (Since 2017)
  4. Member, China Consortium of Elite Teaching Hospitals for Residency Education (Since 2017)
  5. Examiner, Royal College of Physicians (UK) MRCPUK PACES
  6. Expert Grant Reviewer, The National Medical Research Council, Singapore (Since 2013)
  7. Member, Education Committee, Hong Kong Academy of Medicine (Since 2018)
  8. Member, Education & Accreditation Committee, Hong Kong Medical Council (Since 2018)
  9. Member, Licentiate Examination Subcommittee, Hong Kong Medical Council (Since 2017)
  10. Secretary, Infectious Diseases Board, Hong Kong College of Physicians (Since 2018)
  11. Council Member, Hong Kong Society of Infectious Diseases (Since 2013)
  12. Member, Expert Advisory Panel (EAP) in Infectious Diseases Research, Food and Health Bureau (Since 2018)
  13. Member, Health and Medical Research Fund Grant Review Board, Food and Health Bureau (Since 2014)
  14. Member, Research Response Group for Emerging Health Threats, Food and Health Bureau (Since 2013)
  15. Member, Senate Committee on Discontinuation, the University of Hong Kong (Since 2013)
  16. Member, Work Group on Clinical Management for Avian Influenza (H7N9) and Novel Coronavirus (NCoV), Hospital Authority (Since 2013)
  17. Member, Central Committee of Infectious Diseases and Emerging Responses (CCIDER), Hospital Authority (Since 2012)
  18. Member, Subcommittee of AIDS Trust Fund, Department of Health (Since 2018)
  19. Member, Subcommittee of HA Infectious Diseases & Infection Control Training, Department of Health (Since 2012)
  20. Member, Committee for Infectious Disease & Infection Control Training, Centre of Health Protection (Since 2012)
  21. Member, Task Force on Clinical Management of Infection, Centre of Health Protection (Since 2012)
  22. Section Editor, BMC Infectious Diseases (Since 2016)
  23. Associate Editor, Vaccine Journal
  24. Associate Editor, Journal of Interventional Gastroenterology (Since 2012)
  25. Associate Editor, Interhospital Multi-disciplinary Program on Antimicrobial Chemotherapy (IMPACT) Guideline (Editions 4 & 5)
  26. Assistant Dean (Clinical Curriculum & Assessment), LKS Faculty of Medicine, The University of Hong Kong (2017)